These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24707897)

  • 1. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.
    Barret M; Antoun S; Dalban C; Malka D; Mansourbakht T; Zaanan A; Latko E; Taieb J
    Nutr Cancer; 2014; 66(4):583-9. PubMed ID: 24707897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
    Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
    Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of body composition on chemotherapy toxicities in non-metastatic colorectal cancer patients: a systematic review.
    Choi CS; Kin K; Cao K; Hutcheon E; Lee M; Chan STF; Arafat Y; Baird PN; Yeung JMC
    ANZ J Surg; 2024 Mar; 94(3):327-334. PubMed ID: 38059530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
    Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
    PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
    Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
    Antoun S; Bayar MA; Dyevre V; Lanoy E; Smolenschi C; Ducreux M
    BMC Cancer; 2019 Aug; 19(1):847. PubMed ID: 31462288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.
    Gallois C; Artru P; Lièvre A; Auclin E; Lecomte T; Locher C; Marthey L; Zaimi Y; Faroux R; Pernot S; Barret M; Taieb J
    Eur J Cancer; 2019 Sep; 119():35-43. PubMed ID: 31415985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
    Yücel KB; Aydos U; Sütcüoglu O; Kılıç ACK; Özdemir N; Özet A; Yazıcı O
    Cancer Chemother Pharmacol; 2024 May; 93(5):497-507. PubMed ID: 38436714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition measures as a determinant of Alpelisib related toxicity.
    Shachar E; Raphael A; Katz U; Kessner R; Shachar SS
    Breast Cancer Res Treat; 2024 Jul; 206(2):369-376. PubMed ID: 38584192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
    Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
    Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
    Jehn CF; Böning L; Kröning H; Pezzutto A; Lüftner D
    Eur J Cancer; 2014 May; 50(7):1269-75. PubMed ID: 24503027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
    Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; van Hazel G; Wilson K; Simes J; Shapiro JD
    J Clin Oncol; 2016 Jul; 34(19):2258-64. PubMed ID: 27114605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body composition and outcome in patients undergoing resection of colorectal liver metastases.
    van Vledder MG; Levolger S; Ayez N; Verhoef C; Tran TC; Ijzermans JN
    Br J Surg; 2012 Apr; 99(4):550-7. PubMed ID: 22246799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.